5 recruiting, 3 completed. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Recruiting 5, Completed 3 |
Follow Chronic Inflammatory Demyelinating Polyneuropathy: new trials by email Literature Review of Chronic Inflammatory Demyelinating Polyneuropathy trials Research Report on Chronic Inflammatory Demyelinating Polyneuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immune globulin (human) 10% solution for intravenous administration - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Kedrion S.p.A. | 161 | 2026-10-01 | 2026-09-11 |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Empasiprubart IV, Placebo IV - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 160 | 2025-09-16 | 2026-10-27 |
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP empasiprubart, IVIg, empasiprubart-placebo - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 218 | 2025-08-22 | 2026-10-30 |
| A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) Claseprubart, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Dianthus Therapeutics | 256 | 2025-02-10 | 2026-10-28 |
| A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) riliprubart, Placebo, IVIg - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Sanofi | 160 | 2024-08-21 | 2026-10-19 |
| Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. NPB-01 - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Completed | Nihon Pharmaceutical Co., Ltd | 49 | 2013-04-01 | 2016-01-20 |
| Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) IgPro20 (low dose), Placebo, IgPro10 - Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy | Phase 3 | Completed | CSL Behring | 208 | 2012-03-01 | 2018-07-05 |
| Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy 10% liquid formulation of human immunoglobulin - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Completed | CSL Behring | 31 | 2010-11-01 | 2024-06-25 |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (8) · Polyradiculoneuropathy (1)
Autoimmune Diseases (8) · Autoimmune Diseases of the Nervous System (8) · Chronic Disease (8) · Demyelinating Diseases (8) · Disease Attributes (8) · Immune System Diseases (8) · Nervous System Diseases (8) · Neuromuscular Diseases (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Peripheral Nervous System Diseases (8) · Polyneuropathies (8) · Polyradiculoneuropathy (7)
Immunoglobulins, Intravenous (4) · Administration, Intravenous (1) · Hizentra (1) · Immunoglobulins (1) · Solutions (1)
CSL Behring (2) · argenx (2) · Dianthus Therapeutics (1) · Kedrion S.p.A. (1) · Nihon Pharmaceutical Co., Ltd (1) · Sanofi (1)
France (6) · Japan (6) · United States (6) · Germany (5) · Israel (5) · Italy (5) · Poland (5) · United Kingdom (5) · Argentina (4) · Belgium (4) · Brazil (4) · Czechia (4) · Netherlands (4) · Spain (4) · Australia (3)
PMID 23781960, PMID 27455854, PMID 28594116, PMID 28768822, PMID 29122523, PMID 42578463
2009 (1), 2023 (1), 2025 (1)